Europe’s new HTA reality: The JCA, one year on
Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.
Newsletters and Deep Dive digital magazine
Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.
May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.
The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.
Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs
Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?
Editor's Picks
Newsletters and Deep Dive
digital magazine